Henning Schwanhäusser is a Board member of T-CURX. Henning is a serial entrepreneur and investor in a number of high-tech start-up companies in IT and Biotech. Henning was co-founder & Board member of Basel, Switzerland, based NBE-Therapeutics and instrumental for developing the company's strategy leading to the successful trade-sale of NBE-Therapeutics to Boehringer Ingelheim, Germany, for $ 1.4bn in 2021. He is currently advisor or Dahlia Robotics in Munich, Germany and investor in Viou in London, GB. Henning was founder and CEO of IT company AccapiStudio SRL, in Vicenza, Italy, from 2002-2015, a member of the supervisory board of Sketchin from 2013-2016, a company in Ticino, Switzerland, and he was seed-investor in SparkFabrik in Milano, Italy, from 2012-2019. Since 2021 Henning is also a member of the Board of Advisors of Schwanhäußer Industrie Holding GmbH & Co. KG in Heroldsberg, Germany. Henning holds a diploma in Business Engineering from the University of Padova, Italy, and a diploma in Technology Entrepreneurship from the Executive School of Management of the University St. Gallen, Switzerland.